Clinical Trials Logo

Clinical Trial Details — Status: No longer available

Administrative data

NCT number NCT00575549
Other study ID # 0311-07-FB
Secondary ID
Status No longer available
Phase
First received
Last updated

Study information

Verified date October 2023
Source University of Nebraska
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

The purpose of this study is to prospectively analyze and compare conventional stress echocardiograms and real-time myocardial contrast stress echocardiograms; and to determine the effect of contrast agents used during real-time myocardial contrast stress echocardiograms on serum troponin I levels.


Description:

To compare two different stress echocardiograms (conventional Stress echocardiograms or Real-time Myocardial Contrast Stress Echocardiograms) that are in routine clinical use. The information, including the digital images that are collected during the stress tests is used to determine if the usse of specialized imaging techniques and ultrasound contrast can better detect blockage in blood flow to the heart and predict how patients outcome may be affected by this detection of a blockage.


Recruitment information / eligibility

Status No longer available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Male or female - Age > 19 years - Scheduled for a stress echocardiography - Are conscious and coherent, and able to communicate effectively with trial personnel - For troponin evaluation, only hospitalized patients who had a troponin level drawn in the morning of and prior to stress echocardiogram will be included. Exclusion Criteria: - Pregnant and breast feeding women are excluded from participation because of the possibility of a bias as CSE is routinely used in pregnant patients secondary to lack of human studies to determine the fetal risk of use of Definity. - Age < 19 years old - Known or suspected hypersensitivity to ultrasound contrast agents or other drugs used for the study - Possibility that potential subject may be pregnant - Studies where RT-MCE was specifically requested by the ordering physician

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Dobutamine: Perflutren Lipid Microsphere
Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min

Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
University of Nebraska Bristol-Myers Squibb

Country where clinical trial is conducted

United States,